Zydus Lifesciences Limited (Zydus), on March 11, 2025, entered into agreements with PAI and two minority shareholders of Amplitude Surgical to acquire blocks of shares representing in aggregate 85.6% of Amplitude Surgical's share capital and voting rights at a price of €6.25 per share and a total consideration of €256 million (block acquisition).

As all conditions precedent to the completion have now been fulfilled, and the Block Acquisition has been subsequently completed on July 29, 2025, Zydus now holds 85.6% of the share capital and voting rights of Amplitude Surgical.

Olivier Jallabert will remain in his role as CEO of Amplitude Surgical, and, as part of the block acquisition, has invested into the company which has completed the block acquisition.

In the context of the Block Acquisition, Amplitude Surgical has terminated with effect as of July 28, 2025 its liquidity contract entered into between Amplitude Surgical, Oddo BHF and Natixis dated June 19, 2018.

Zydus will file a simplified mandatory tender offer on July 30, 2025 for all the remaining outstanding shares of Amplitude Surgical at a price of €6.25 per share, at par with the price paid for the Block Acquisition. Considering the certain undertakings to tender received from seven shareholders representing in aggregate 4.7% of share capital and voting rights, Zydus will be able to secure more than 90% of the capital and voting rights of Amplitude Surgical upon completion of the Offer and will subsequently request the implementation of a squeeze-out.

Subject to the French Financial Market Authority's (Autorité des marches financiers, AMF) clearance of the Offer, it is currently envisaged that the Offer may be opened in September 2025. No other regulatory approval will be required.

On July 28, 2025, the Board of Directors of Amplitude Surgical unanimously welcomed the Offer and on the same date issued its reasoned opinion following receipt of the fairness opinion from Finexsi, appointed as independent expert for the purpose of the Offer.